One of the comparisons in BIG 1-98 was the effect of monotherapy with letrozole (an aromatase inhibitor) or tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor–positive breast cancer on the risk of death. The gene discussed is CYP19A1; the disease is breast carcinoma.